
@article{ref1,
title="Incidence of dog bite and anti-rabies vaccine utilization in the University of Benin Teaching Hospital, Benin City, Nigeria: A 12-year assessment",
journal="Vaccine",
year="2010",
author="Aghahowa, S. E. and Ogbevoen, R. N.",
volume="28",
number="30",
pages="4847-4850",
abstract="<p>AIM: To assess the incidence of dog bite and utilization of anti-rabies vaccine between January 1997 and December 2008. METHODS: Reported cases of dog bite from archives were collected and analyzed in the Accident and Emergency Centre of the University of Benin Teaching Hospital, Benin City, Nigeria. RESULT: A total of 143 cases were reported and none was previously immunized. They were between 14 and 64 years with male and female ratio 7.2:1. Among them, 53% cases were reported within 24h, 36% cases were reported after 30 days and 11% cases reported after two months of affliction. Limbs were most afflicted. Forty-two 29.37%. patients had multiple sites of bite. Minor bleeding was in 71.33%. victims. Five hundred and eighty-seven doses of Rabipur((R)) brand of anti-rabies vaccines of which 65.42% were administered intradermally and 34.58% were administered intramuscularly. Only 71% of the victims were treated with Imogam Rabies((R)) brand of Rabies Immunoglobulin G. Sixty-three dog owners claimed that their dogs were vaccinated. Of the total victims, 13795.80%. completed their routine 5 days anti-rabies regimen. Forty-seven (32.87%) were hospitalized; maximum duration was 167+/-0.71h. Ciprofloxacin and paracetamol were most frequently used antibacterial and anti-inflammatory agents, respectively. All had anti-tetanus sera. One had traditional medication prior to report presented with clinical sign of hydrophobia. He died despite therapy. CONCLUSION: The incidence of dog bite although rare, there is need for adequate procurement and stocking of anti-rabies vaccine to meet the need of the afflicted in this region.<p /> <p>Language: en</p>",
language="en",
issn="0264-410X",
doi="10.1016/j.vaccine.2010.04.004",
url="http://dx.doi.org/10.1016/j.vaccine.2010.04.004"
}